

KAZIA THERAPEUTICS

Investor Newsletter

SEPTEMBER 2019

From the CEO



Dr James Garner
*CEO and
Managing Director*

Dear Investors,

Looking back over the past three months for Kazia, so much exciting progress has been made that it is almost difficult to choose the highlights. Nevertheless, as we head into the fourth quarter with key data read-outs imminent, we are confident of further significant progress to come.

In July, we announced a new clinical trial collaboration with Memorial Sloan Kettering Cancer Center (MSK), to look at GDC-0084 in combination with radiotherapy for metastatic brain cancer. MSK is generally considered among the top five cancer hospitals in the world, and we are thrilled to be working with them. We now have five active clinical trials with GDC-0084, four of which are primarily funded by external sources.

In September, we reported the first data from one of these clinical collaborations – encouraging early results from the study in DIPG, a childhood brain cancer, at St Jude Children's Research Hospital. We look forward to seeing further results from this study before long.

Meanwhile, the Cantrixil phase I study has been progressing extremely well and is now close to completion, with completion expected in the first half of next year. New data will be reported at the upcoming ESMO conference in late September, and this should help to provide further insight into the potential efficacy of Cantrixil.

Given these many achievements, it was hugely gratifying for the entire Kazia team to find ourselves a winner of the inaugural Trans-Tasman Innovation and Growth Awards, administered by the Australia New Zealand Leadership Forum (ANZLF) and presented by New Zealand Prime Minister, Jacinda Ardern, and Australian Trade Minister, Simon Birmingham.

This award testifies to the talent and hard work of the entire Kazia team, and I am proud to work with such dedicated and resourceful colleagues.

Dr James Garner

In the News



20 September 2019

Kazia presents GDC-0084 at EANO conference in Lyon, France



12 September 2019

St Jude phase I study in DIPG reports MTD and completion of Part A



11 September 2019

Kazia a winner in ANZLF Trans-Tasman Innovation & Growth Awards



13 August 2019

Cantrixil phase I study completes recruitment



22 July 2019

Kazia announces phase I clinical collaboration with Memorial Sloan-Kettering

Follow our Story



www.KaziaTherapeutics.com



[Kazia Therapeutics](#)



[@KaziaTx](#)



[KaziaTx](#)

Kazia wins inaugural ANZLF Award

Kazia was immensely honoured to be named a winner in the inaugural Trans-Tasman Innovation and Growth Awards, created by the Australia and New Zealand Leadership Forum. The Award was presented at a dinner in Auckland on 12 September by New Zealand Prime Minister, Jacinda Arden, and Australian Trade Minister, Simon Birmingham.



The ANZLF was established in 2004 to bring business and government together to help Australia and New Zealand prosper. The Forum enables discussion between senior business and government leaders about ways to improve business and trade between Australia and New Zealand. The ANZLF is the only high-level and broad-based bilateral Australia-New Zealand business forum that engages closely with governments on both sides of the Tasman.



Kazia's Programs at a Glance

GDC-0084

[NCT03522298](#)
Phase II study in glioblastoma (most common brain cancer) (led by Kazia Therapeutics) Part A successfully completed; Part B currently recruiting

[NCT03765983](#)
Phase II study in breast cancer brain metastases (led by Dana-Farber Cancer Inst.) Recruiting

[NCT03994796](#)
Phase II study in brain mets. (led by Alliance for Clinical Trials in Oncology) Recruiting

[NCT03696355](#)
Phase I study in DIPG (led by St Jude Children's Research Hospital) Part A successfully completed; Part B currently recruiting

(TBD)
Phase I study in brain mets. (led by Memorial Sloan Kettering Cancer Center) Start-up

Cantrixil

[NCT02903771](#)
Phase I study in treatment-resistant ovarian cancer (led by Kazia Therapeutics) Fully-recruited; interim data to be presented at ESMO (Sept. 2019)

“Put simply, our company exists to try and change the reality for patients with cancer. Our dream is that this devastating diagnosis will one day mean nothing more than a case of appendicitis or a broken bone or a dental abscess.”

Dr James Garner, CEO of Kazia Therapeutics
in his acceptance speech for the Award

The Trans-Tasman Innovation and Growth Awards were established to recognise successful emerging companies in Australia and New Zealand that exemplify collaboration, growth, innovation, and diversity. The Award Dinner was attended by several hundred senior business leaders from both countries. As part of the Award, Kazia receives a AU\$ 20,000 prize, and participation in several forums and networking opportunities over the next twelve months.



GDC-0084 Chemotherapy Combinations


A team at MD Anderson Cancer Center in Houston has explored GDC-0084 together with arsenic trioxide (ATO) in a preclinical model of glioma, the family of brain cancers to which glioblastoma belongs.

The MD Anderson team found that the combination of GDC-0084 and ATO was more effective than either drug in isolation. An abstract was published in the journal [Cancer Research](#).

So What? ATO is not a common treatment for glioblastoma, but the data does help to suggest how GDC-0084 may be combined more broadly with other agents to further enhance its efficacy.

Cantrixil at AACR

Kazia's Daniel Berg presented a poster at the AACR Annual Conference in Atlanta summarising data from Part A of the Cantrixil phase I study in ovarian cancer. The data showed the drug to be generally well-tolerated with a maximum tolerated dose (MTD) of 5 mg/kg. There were some encouraging early signals of efficacy, which will be explored further in Part B of the study. The poster is available from the [Kazia website](#).



Progress in DIPG


Dr Ryan Duchatel, working with Professor Matt Dun at the University of Newcastle, presented a poster at the Society for Neuro-Oncology's Pediatric Translational Research Meeting in San Francisco.

Dr Duchatel's poster provided further data on the work from the Dun laboratory, identifying potential combinations of GDC-0084 that may be used to treat DIPG, an aggressive form of childhood brain cancer. The abstract was published in the journal [Neuro-Oncology](#).

So What? The ongoing Newcastle research has provided very relevant insight into how GDC-0084 may be used in this extremely challenging cancer, that may be profoundly useful for future clinical studies.

European Debut for GDC-0084

Kazia's Dr Jeremy Simpson presented a poster at the EANO Annual Conference in Lyon, France outlining the ongoing phase II study of GDC-0084 in glioblastoma. The poster represented the first engagement with European clinicians by Kazia. The lead author and co-presenter was Professor Patrick Wen from Dana-Farber Cancer Institute. A copy of the poster is available from the [Kazia website](#).



Novel Analytical Methods for GDC-0084

Dr Clinton Stewart's team at St Jude Children's Research Hospital had a paper accepted on an analytical method for measuring the concentration of GDC-0084 in biological samples. The abstract is available via the journal [Biomedical Chromatography](#).

So What? Kazia has proprietary analytical methods to measure GDC-0084, but the ability of world-class laboratories such as St Jude to develop their own procedures with relative ease makes it easier to work with the drug and encourages further novel research with GDC-0084. Dr Stewart's work is currently being used to measure drug concentrations in the ongoing phase I study at St Jude.

Upcoming Scientific Conferences



27 September – 1 October 2019
European Society for Medical Oncology
Barcelona, Spain



20 – 24 November 2019
Society for Neuro-Oncology
Phoenix, AZ, USA



10 – 14 December 2019
San Antonio Breast Cancer Symposium
San Antonio, TX, USA



10 – 11 December 2019
Glioblastoma Drug Development Summit
Boston, MA, USA

Spotlight on Scientific Conferences



Daniel Berg
Clinical Program Director
– Cantrixil

In this interview, Kazia's Daniel Berg talks about the important role that scientific conferences, meetings, and journal publications play in bringing the Kazia story to a wider audience

How do companies such as Kazia arrange to present at scientific conferences?

To be selected for presentation at a conference generally means that a committee of clinicians and scientists have decided that the project in question is of sufficiently high quality and of interest to conference attendees. It is a very positive endorsement of a project to be selected for the major conferences such as AACR or ESMO.

Who are the attendees at these conferences?

The larger conferences are generally attended by the top specialists in oncology. Some of the smaller conferences are tailored to a more targeted audience, such as brain cancer or childhood cancer. Either way, presenting gives us an opportunity to raise awareness of our programs among a much wider range of clinicians. Some of those clinicians subsequently participate in Kazia clinical studies, or refer patients to our studies.

Wouldn't the clinicians already be aware of GDC-0084 and Cantrixil?

Even in under-served cancers such as ovarian cancer and brain cancer, there are an enormous number of drugs generating data, and clinicians are extremely busy people. They generally don't have the opportunity to proactively seek us out, and so we have to find ways to go to them.

Is it only about clinicians?

Not at all. Many scientific conferences are attended by representatives of major pharmaceutical companies, so these events provide critical opportunities for partnering discussions. The larger meetings are also attended by specialist investors, so it's a great opportunity to make them aware of Kazia for future reference. We also meet patient advocacy groups, who are increasingly important for drugs in development. Overall, the networking opportunity is priceless.


How do you balance conference participation with corporate continuous disclosure requirements?

We are always very mindful of continuous disclosure. In general, whenever significant new data is released at a conference, we immediately put out an ASX announcement which provides the complete data set, as well as a plain English summary. For some releases, we also put out explanatory videos or other pieces to help investors digest the new information. All our posters and presentations end up on the Kazia website for ease of access.

What can we look forward to in terms of upcoming conference presentations?

It has already been an exceptional year, with posters at the very prestigious AACR meeting (Cantrixil), and at the EANO meeting (GDC-0084). We have ESMO coming up imminently, with new Cantrixil data to be presented, followed by SNO, the key brain cancer meeting, and a couple of more specialist conferences before the end of the year. We have actually had more conference posters and presentations for both our programs in 2019 than ever before, which says a lot about the quality of the work and the pace with which it is progressing.

Market Watch



Market Cap: AU\$ 34 million

52W Range: AU\$ 0.32 – 0.58

Issued Shares: 62 million